Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
biotechdaily.com
Drug Discovery
Features Subscription Partner Sites Journal Info
GLOBETECH PUBLISHINGPZ HTL SA

Candidate Leukemia Drugs Target Activity of Cooperation Response Genes

By BiotechDaily International staff writers
Posted on 11 Sep 2012


Cancer researchers have identified a set of genes that operate in a cooperative fashion to regulate the growth and survival of leukemia stem cells (LSCs), a biologically distinct subpopulation of myeloid leukemias with reduced cell cycle activity and increased resistance to chemotherapy.

Leukemia is known for being particularly resistant to treatment. In part, this resistance is due to the LRC population that remains unaffected by chemotherapy and provides a source of new cancer cells that cause relapse of the disease following treatment.

Investigators at the University of Rochester (New York, USA) used both a primary mouse model and human leukemia specimens to study the genes that control LRC growth and survival. To this end they adapted an approach based on identification of genes synergistically dysregulated by cooperating oncogenes. This class of genes - similar to a pool of approximately 100 genes that was found to cooperate to promote colon cancer - had been nicknamed “cooperation response genes” (CRGs).

Results published in the August 2, 2012, online edition of the journal Cell Stem Cell revealed that approximately 70 CRGs played a role in growth and survival of both primitive leukemia cells and more mature leukemia cells. Silencing the expression of these CRGs in the mice model reduced leukemia growth.

The investigators screened hundreds of known drug compounds for the ability to disrupt leukemia CRG activity. Two compounds were identified and are now being evaluated as possible drug candidates.

“No one else has used the targeting of CRGs as criteria to look for drugs that might treat cancer,” said senior author Dr. Craig T. Jordan, professor of medicine at the University of Rochester. “By using the CRG approach, we found drug compounds that might never have been selected, based on their documented mechanism of action. Our work is both basic and translational, and is an example of a terrific collaboration. We were able to use the latest technology to expand very strong basic laboratory concepts and conduct an intriguing analysis that may yield new insights for treatments of leukemia.”

Related Links:
University of Rochester




Standard Probes
Standard Probes
Blot Scanner
Blot Scanner
Microbioreactor
Microbioreactor

More Products

Latest Drug Discovery News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Whitepaper
Veolia WATER:
Why pure water is important in modern chromatography

Download Whitepaper
Featured Video
BioTek:

View Video
Events
The 23rd Annual Scientific Meeting
09 Jul 2013 - 10 Jul 2013


27th Annual Symposium of the Protein Society
20 Jul 2013 - 24 Jul 2013


AACC 2013 – Annual Meeting of the American Association for Clinical Chemistry
28 Jul 2013 - 01 Aug 2013


More events
Latest Issue

View Digital Edition
Subscribe / Renew
GLOBETECH PUBLISHING'
PZ HTL SA
VISION-SCIENCES, INC.
  biotechdaily.com Copyright © 2000-2013 Globetech Media. All rights reserved.
Privacy Policy